These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 8714794)

  • 1. The underestimated long term medical and economic consequences of rheumatoid arthritis.
    Pincus T
    Drugs; 1995; 50 Suppl 1():1-14. PubMed ID: 8714794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The burden of rheumatoid arthritis: facts and figures.
    Callahan LF
    J Rheumatol Suppl; 1998 Jul; 53():8-12. PubMed ID: 9666412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What are the costs to society and the potential benefits from the effective management of early rheumatoid arthritis?
    March L; Lapsley H
    Best Pract Res Clin Rheumatol; 2001 Mar; 15(1):171-85. PubMed ID: 11358421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial.
    Maetzel A; Strand V; Tugwell P; Wells G; Bombardier C
    Pharmacoeconomics; 2002; 20(1):61-70. PubMed ID: 11817993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology and burden of illness of rheumatoid arthritis.
    Kvien TK
    Pharmacoeconomics; 2004; 22(2 Suppl 1):1-12. PubMed ID: 15157000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How can the risk of long-term consequences of rheumatoid arthritis be reduced?
    Pincus T; Sokka T
    Best Pract Res Clin Rheumatol; 2001 Mar; 15(1):139-70. PubMed ID: 11358420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 'side effects' of rheumatoid arthritis: joint destruction, disability and early mortality.
    Pincus T; Callahan LF
    Br J Rheumatol; 1993 Mar; 32 Suppl 1():28-37. PubMed ID: 8448634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Societal cost of rheumatoid arthritis patients in the US.
    Birnbaum H; Pike C; Kaufman R; Marynchenko M; Kidolezi Y; Cifaldi M
    Curr Med Res Opin; 2010 Jan; 26(1):77-90. PubMed ID: 19908947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic and quality-of-life impact of NSAIDs in rheumatoid arthritis: A conceptual framework and selected literature review.
    Gabriel SE; Matteson EL
    Pharmacoeconomics; 1995 Dec; 8(6):479-90. PubMed ID: 10160078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients.
    Mennini FS; Marcellusi A; Gitto L; Iannone F
    Clin Drug Investig; 2017 Apr; 37(4):375-386. PubMed ID: 28074337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A multicenter cross-sectional study on the health related quality of life of patients with rheumatoid arthritis using a revised Japanese version of the arthritis impact measurement scales version 2 (AIMS 2), focusing on the medical care costs and their associative factors].
    Hashimoto A; Sato H; Nishibayahi Y; Shiino Y; Kutsuna T; Ishihara Y; Hoshi K; Fujimori J; Tsuboi S; Kondo H; Akizuki M; Moroi Y; Yoshida S
    Ryumachi; 2002 Feb; 42(1):23-39. PubMed ID: 11925904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
    Bansback NJ; Regier DA; Ara R; Brennan A; Shojania K; Esdaile JM; Anis AH; Marra CA
    Drugs; 2005; 65(4):473-96. PubMed ID: 15733011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study.
    Lajas C; Abasolo L; Bellajdel B; Hernández-García C; Carmona L; Vargas E; Lázaro P; Jover JA
    Arthritis Rheum; 2003 Feb; 49(1):64-70. PubMed ID: 12579595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand.
    Osiri M; Maetzel A; Tugwell P
    J Rheumatol; 2007 Jan; 34(1):57-63. PubMed ID: 17183621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomic aspects of non-steroidal anti-inflammatory drug gastropathy.
    Walan A; Wahlqvist P
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S79-88. PubMed ID: 10379474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis.
    Her M; Kavanaugh A
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S107-11. PubMed ID: 23078839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The costs of rheumatoid arthritis.
    Allaire SH; Prashker MJ; Meenan RF
    Pharmacoeconomics; 1994 Dec; 6(6):513-22. PubMed ID: 10155281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 50 years of antirheumatic therapy: the prognosis of rheumatoid arthritis.
    Wolfe F
    J Rheumatol Suppl; 1990 May; 22():24-32. PubMed ID: 2192057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.